68 -2 (76) 2025 - Yusupova M.M. - CAUSES OF PULMONARY HYPERTENSION AND MODERN TREATMENT METHODS

CAUSES OF PULMONARY HYPERTENSION AND MODERN TREATMENT METHODS

Yusupova M.M. - Central Asian Medical University Uzbekistan, Fergana

Resume

This article provides an in-depth analysis of the processes, treatments, treatments and management of pulmonary hypertension. In order to slow down the progression of the disease and improve the quality of treatment for patients, multidisciplinary production and new ones are needed. discusses recent new treatments and therapies for pulmonary hypertension and results

Key words: Pulmonary hypertension, pathophysiological mechanisms, symptoms, prognosis, blood tests, diagnostic tools.

First page

366

Last page

370

For citation:Yusupova M.M. - CAUSES OF PULMONARY HYPERTENSION AND MODERN TREATMENT METHODS//New Day in Medicine 2(76)2025 366-370 https://https://newdayworldmedicine.com/en/new_day_medicine/2-76-2025

List of References

  1. Firstenberg M. S., Abel E., Higgins R. S., Sirak J. H., Sai-Sudhakar C. B., Kilic, A., Crestanello J. (2012, February). Shortness of breath: pulmonary embolism, ischemic heart failure, or both? The role of concomitant surgery. //In TheHeartSurgeryForum 2012;15(1):56-58. https://doi.org/10.1532/HSF98.20111120
  2. Gehlbach B.K., Geppert E. (2004). The pulmonary manifestations of left heart failure. //Chest, 2004;125(2):669-682. https://doi.org/10.1378/chest.125.2.669
  3. Humbert M., McLaughlin V., Gibbs J.S.R., Gomberg-Maitland M., Hoeper M.M., Preston I.R., Souza R., Waxman A., Escribano Subias P., Feldman J. and Meyer G., 2021. Sotatercept for the treatment of pulmonary arterial hypertension. //New England Journal of Medicine 2021;384(13);1204-1215. DOI: 10.1056/NEJMc2107209.
  4. Le Jemtel, T. H., Padeletti, M., & Jelic, S. (2007). Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. //Journal of the American College of Cardiology, 2007;49(2);171-180. https://doi.org/10.1016/j.jacc.2006.08.046
  5. Medvedev A. V., Abubikirov A. F., Zaitseva A. S., Mazaeva L. A., Makaryants N. N., Shmelev E. I. (2021). Characteristics of dyspnea in patients with progressive fibrotic phenotype of interstitial lung diseases associated with coronary heart disease (Медведев, А. В., Абубикиров, А. Ф., Зайцева, А. С., Мазаева, Л. А., Макарьянц, Н. Н., Шмелёв, Е. И.) (2021). Характеристика одышки у больных прогрессирующим фибротическим фенотипом интерстициальных заболеваний легких, ассоциированных с ишемической болезнью сердца. Доктор. Ру, 2021;20(7):58-65. DOI:10.31550/1727-2378-2021-20-7-58-65.
  6. Middleton J.T., Maulik A., Lewis R., Kiely D.G., Toshner M., Charalampopoulos A., Kyriacou A. and Rothman A., 2019. Arrhythmic burden and outcomes in pulmonary arterial hypertension. //Frontiers in medicine 2019;6:169. https://doi.org/10.3389/fmed.2019.00169
  7. Nogueira-Ferreira R., Moreira-Goncalves D., Santos M., Trindade F., Ferreira R., Henriques-Coelho, T. (2018). Mechanisms underlying the impact of exercise training in pulmonary arterial hypertension. //Respiratory medicine 2018;134:70-78. https://doi.org/10.1016/j.rmed.2017.11.022
  8. Poole-Wilson P. A. (1988). The origin of symptoms in patients with chronic heart failure. //European Heart Journal, 1988;9(suppl_H):49-53. https://doi.org/10.1093/eurheartj/9.suppl_H.49
  9. Rossi A., Aisanov Z., Avdeev S., Di Maria G., Donner C.F., Izquierdo J.L., Roche N., Similowski T., Watz H., Worth H. and Miravitlles M., 2015. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. //Respiratory medicine, 2015;109(7):785-802. https://doi.org/10.1016/j.rmed.2015.03.010

    file

    download